Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.71 |
| ▸ | RAB9A | P51151 | 2/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | CTSB | P07858 | 2/20 | 0.53 |
| ▸ | DRD2 | P14416 | 2/20 | 0.49 |
| ▸ | DRD4 | P21917 | 2/20 | 0.49 |
| ▸ | DRD3 | P35462 | 2/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5869108 | 1.00 | NPC1 (0.71) | NPC1RAB9ASMN1; SMN2CTSBDRD2 | |
| SCHEMBL5869095 | 1.00 | NPC1 (0.71) | NPC1RAB9ASMN1; SMN2CTSBDRD2 | |
| SCHEMBL8437528 | 0.87 | NPC1 (0.63) | NPC1RAB9ASMN1; SMN2CTSBDRD2 | |
| SCHEMBL5869432 | 0.87 | NPC1 (0.58) | NPC1RAB9ASMN1; SMN2CTSBTRPV1 | |
| SCHEMBL8256665 | 0.87 | NPC1 (0.58) | NPC1RAB9ASMN1; SMN2CTSBTRPV1 | |
| SCHEMBL5869823 | 0.86 | NPC1 (0.66) | NPC1RAB9ASMN1; SMN2CTSBDRD2 | |
| SCHEMBL5869817 | 0.86 | NPC1 (0.66) | NPC1RAB9ASMN1; SMN2CTSBDRD2 | |
| SCHEMBL5869828 | 0.86 | NPC1 (0.66) | NPC1RAB9ASMN1; SMN2CTSBDRD2 | |
| SCHEMBL5870003 | 0.86 | SMN1; SMN2 (0.51) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7531798 | 0.86 | RAB9A (0.51) | NPC1RAB9ASMN1; SMN2EPHX2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7045532-B2 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-05-16 | — | — | US | disclosed |
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | ACE, ACE2, AGTR2 | NPC1 2323/4885RAB9A 2897/4885SMN1; SMN2 3028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.